Fecal Microbiota Transplantation: A Promising Therapeutic Strategy Targeting the Microbiota-Gut-Brain Axis in Anorexia Nervosa.
- 1Department of Gastroenterology, Shantou University Medical College, Shantou, Guangdong Province, China.
- 2Department of Gastroenterology, The First Affiliated Hospital of Shantou University Medical College, Shantou, Guangdong, People's Republic of China.
Abstract
Purpose
Anorexia nervosa (AN) is a complex psychiatric disorder characterized by self-starvation, body-image disturbance, and serious medical complications. Because current treatments have variable outcomes and relapse is common, the microbiota-gut-brain axis has been investigated as a possible contributor to disease persistence. This review evaluates fecal microbiota transplantation (FMT) as an experimental microbiota-directed strategy for AN.Methods
PubMed, Embase, Scopus, and Google Scholar were searched for relevant studies published from January 1990 to October 2025. Eligible evidence included human reports, animal studies, and mechanistic studies examining FMT or gut-microbiota alterations in AN and related pathways.Findings
Individuals with AN have been reported to show altered microbial diversity and changes in taxa associated with short-chain fatty acid production and inflammation. These findings are heterogeneous and may reflect starvation, diet, medication exposure, or illness-related physiology. Human evidence for FMT in AN is limited to small, uncontrolled studies and case reports, while most mechanistic support comes from animal models or indirect evidence from other conditions.Conclusion
Evidence for FMT in AN remains preliminary and is largely based on uncontrolled human observations and preclinical studies. FMT may alter gut microbial composition and gastrointestinal or metabolic measures, but controlled efficacy data are absent and psychiatric benefits remain unconfirmed. Well-designed controlled trials are needed to establish its safety and clinical efficacy.
Related
- Fecal Microbiota Transplantation in the Treatment Strategy of Inflammatory Bowel Disease: Molecular Mechanisms, Clinical Evidence, and the Transition Toward Defined Microbial Therapeutics
- Targeting BCL11B-mediated JAK2/STAT3 activation: A novel therapeutic strategy for Parkinson’s disease
- Faecal microbiota transplantation for treatment of chronic urticaria with recurrent abdominal pain and food allergy
- The Zα domain of ADAR1: emerging roles in cancer biology and evidence as a promising therapeutic target
- SLC25A39: A key regulator of mitochondrial metabolism and a promising therapeutic target in cancer
BibTeX
@article{kwok2026fecal,
title = {{Fecal Microbiota Transplantation: A Promising Therapeutic Strategy Targeting the Microbiota-Gut-Brain Axis in Anorexia Nervosa.}},
author = {Shawn L Kwok and Yu-Chen Xiao and Xian-Bin Cai},
journal = {Brain and behavior},
year = {2026},
month = oct,
doi = {10.1002/brb3.71852},
url = {https://europepmc.org/article/MED/42952078},
note = {CC BY},
}
RIS
TY - JOUR
TI - Fecal Microbiota Transplantation: A Promising Therapeutic Strategy Targeting the Microbiota-Gut-Brain Axis in Anorexia Nervosa.
AU - Shawn L Kwok
AU - Yu-Chen Xiao
AU - Xian-Bin Cai
PY - 2026
DA - 2026/10/28
JO - Brain and behavior
DO - 10.1002/brb3.71852
UR - https://europepmc.org/article/MED/42952078
AB - Purpose Anorexia nervosa (AN) is a complex psychiatric disorder characterized by self-starvation, body-image disturbance, and serious medical complications. Because current treatments have variable outcomes and relapse is common, the microbiota-gut-brain axis has been investigated as a possible contributor to disease persistence. This review evaluates fecal microbiota transplantation (FMT) as an experimental microbiota-directed strategy for AN.Methods PubMed, Embase, Scopus, and Google Scholar were searched for relevant studies published from January 1990 to October 2025. Eligible evidence included human reports, animal studies, and mechanistic studies examining FMT or gut-microbiota alterations in AN and related pathways.Findings Individuals with AN have been reported to show altered microbial diversity and changes in taxa associated with short-chain fatty acid production and inflammation. These findings are heterogeneous and may reflect starvation, diet, medication exposure, or illness-related physiology. Human evidence for FMT in AN is limited to small, uncontrolled studies and case reports, while most mechanistic support comes from animal models or indirect evidence from other conditions.Conclusion Evidence for FMT in AN remains preliminary and is largely based on uncontrolled human observations and preclinical studies. FMT may alter gut microbial composition and gastrointestinal or metabolic measures, but controlled efficacy data are absent and psychiatric benefits remain unconfirmed. Well-designed controlled trials are needed to establish its safety and clinical efficacy.
SN - 2162-3279
ER -